Can a common diabetes pill block a side effect of another?
NCT ID NCT07053319
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study looks at how two diabetes drugs, empagliflozin and pioglitazone, interact in the body. Researchers want to see if pioglitazone can reduce the ketones (a type of acid) that empagliflozin sometimes produces. The study involves 64 adults with type 2 diabetes and measures glucose and ketone levels after taking the drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin and Pioglitazone
What this could lead to
If it works, this could help doctors understand how to better combine diabetes drugs to avoid side effects like high ketones.
What could go wrong
This is a very early, small study (Phase 1, 64 people) looking at body chemistry, not at long-term outcomes. Results may not lead to any change in treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Diabetes Institute/UH
RECRUITINGSan Antonio, Texas, 78229-3900, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact